Drug Profile
Darolutamide - Bayer HealthCare/Orion
Alternative Names: BAY-1841788; Darramamide; NUBEQA; ODM 201Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Orion
- Developer Bayer HealthCare; Dana-Farber Cancer Institute; Latin American Cooperative Oncology Group; Orion; UNICANCER
- Class Amides; Antiandrogens; Antineoplastics; Chlorobenzenes; Nitriles; Pyrazoles; Small molecules
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Prostate cancer
- Phase II Triple negative breast cancer
Most Recent Events
- 13 Mar 2024 Swiss Group for Clinical Cancer Research terminates a phase II trial in Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in France, Italy, Spain and Switzerland (PO), due to lack of financial support from the decision board (NCT02933801)
- 25 Jan 2024 Updated efficacy and adverse events data from a phase III ARASENS trial in Prostate cancer presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
- 20 Oct 2023 Efficacy data from the phase III ARAMIS trial in Prostate cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)